Associated Papers
Distinct and convergent effects of SF3B1 mutations in human breast cancer.
Bergman RE et al.
Proceedings of the National Academy of Sciences of the United States of America, 2025
Splicing factor 3b subunit 1 mutation patterns and prognostic implications in myelodysplastic syndromes, acute myeloid leukemia, and chronic lymphocytic leukemia: A retrospective study of 1691 cases.
Qiao C et al.
Cancer, 2025
Germline DNA Repair Gene Mutations and Clonal Hematopoiesis (CH) in 24,849 Patients with BRCA-Associated Cancers.
Marshall CH et al.
Cancers, 2025
Risk prediction for clonal cytopenia: multicenter real-world evidence.
Xie Z et al.
Blood, 2024
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts.
Choi IY et al.
Blood Advances, 2024
Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms.
Winter S et al.
Leukemia, 2024
Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations.
Kandarpa M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape.
Boddu PC et al.
Molecular Cell, 2024
Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation.
Rombaut D et al.
Nature Communications, 2024
Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or SF3B1 Mutations: The Improved Clinical Utility of World Health Organization and International Consensus Classification 2022 Definitions, a Single-Centre Retrospective Chart Review.
Mortuza S et al.
Current Oncology (toronto, Ont.), 2024
Mining cancer genomes for change-of-metabolic-function mutations.
Tu KJ et al.
Communications Biology, 2023
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts.
Choi IY et al.
Research Square, 2023
Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation.
Boy M et al.
Nature Communications, 2023
Compartment-specific mutational landscape of clonal hematopoiesis.
Hartmann L et al.
Leukemia, 2022
The longitudinal dynamics and natural history of clonal haematopoiesis.
Fabre MA et al.
Nature, 2022
An improved molecular inversion probe based targeted sequencing approach for low variant allele frequency.
Biezuner T et al.
Nar Genomics and Bioinformatics, 2022
Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
Janusz K et al.
Annals of Hematology, 2021
Complex landscape of alternative splicing in myeloid neoplasms.
Hershberger CE et al.
Leukemia, 2021
Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.
Vantyghem S et al.
Haematologica, 2021
The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing.
Dalton WB et al.
Blood Advances, 2020
Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
Tang Y et al.
Critical Reviews in Oncology/hematology, 2019
Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes.
Cedena MT et al.
Oncotarget, 2017
Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts.
Martín I et al.
Blood Cancer Journal, 2017
Distinct molecular genetics of chronic lymphocytic leukemia in Taiwan: clinical and pathogenetic implications.
Wu SJ et al.
Haematologica, 2017
Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms.
Bartels S et al.
Oncotarget, 2016
SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients.
Lasho TL et al.
Leukemia, 2012
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Malcovati L et al.
Blood, 2011